Evaluation of the Efficacy, Safety and Tolerability of BZ371A in Women with Sexual Arousal Disorder

NCT06116045

Status	RECRUITING
Phase	Phase 2
Sponsor	Biozeus Biopharmaceutical S.A.
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (7)

- Women between the ages 21 and 60;
- Pre-menopausal or post-menopausal women may be included;
- May or may not be taking female sex hormones (estrogen with or without progesterone, or their derivatives);
- FSAD, defined as the inability, persistent or recurrent, to obtain or maintain until the conclusion of sexual activity an adequate genital response to sexual arousal (lubrication, warmth and enlargement of the clitoris);
- Women with FSAD who present marked suffering or interpersonal difficulties;

... and 2 more (see full listing online)

Exclusion (29)

- Women who do not agree to use a contraceptive method and who have the capacity to become pregnant during the study;
- Women who do not agree to attempt sexual activity at least twice a week while taking the study medication;
- History of unresolved sexual trauma or abuse;
- Diagnosis of vaginismus, genitopelvic pain/penetration disorder and/or sexual aversion disorder;
- Uncontrolled diabetes at screening visit (HbA1C \> 10%);

... and 24 more (see full listing online)

Locations (1 total)

Centro de Pesquisa Clínica Multiusuário (CePeM), Rio de Janeiro, Rio de Janeiro, Brazil